Alireza Naderi Sohi told IRNA on Thursday that the achievement was published in an article entitled “Development of an mRNA-LNP Vaccine against SARS-CoV-2: Evaluation of Immune Response in Mouse and Rhesus Macaque” in the journal Vaccines.
The technology was monopolized by two German and American companies, but Iranian scientists managed to achieve the technology despite the limitations in supplying laboratory material due to US sanctions, according to the scientist.
Naderi who is one of the authors of the article said that the jury of the journal acknowledged that some cases in the article were even better elaborated than the similar literature for Moderna and Pfizer.
Unlike other vaccine development methods, there is no cell culture in the mRNA method and the production process is therefore faster and cheaper, Naderi highlighted.
He also said that the larger part of clinical study on animals for this vaccine development technology has been carried out and it can enter human clinical test once this phase is finished and Food and Drug Administration authorization is secured.
9416**9417
Follow us on Twitter @IrnaEnglish
Your Comment